Mizuho upgraded shares of Iqvia (NYSE:IQV) from a neutral rating to a buy rating in a research report sent to investors on Friday morning, Benzinga reports. Mizuho currently has $175.00 price objective on the medical research company’s stock, up from their prior price objective of $150.00.
Several other research firms have also commented on IQV. Argus lifted their price target on Iqvia from $140.00 to $160.00 and gave the stock a buy rating in a research report on Monday, February 25th. They noted that the move was a valuation call. Stifel Nicolaus upped their price objective on Iqvia from $167.00 to $178.00 and gave the stock a buy rating in a report on Wednesday, June 19th. William Blair reiterated an outperform rating on shares of Iqvia in a research report on Wednesday, June 19th. Leerink Swann assumed coverage on Iqvia in a research report on Tuesday, May 28th. They set an outperform rating and a $136.38 target price on the stock. Finally, Barclays upped their price objective on Iqvia from $160.00 to $167.00 and gave the company an overweight rating in a research report on Monday, March 18th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company. Iqvia has an average rating of Buy and an average target price of $153.65.
Shares of NYSE:IQV opened at $158.67 on Friday. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.14 and a quick ratio of 1.14. The stock has a market cap of $31.30 billion, a P/E ratio of 30.99, a price-to-earnings-growth ratio of 1.92 and a beta of 0.77. Iqvia has a 12-month low of $97.64 and a 12-month high of $159.54.
In other Iqvia news, insider Kevin C. Knightly sold 46,080 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $138.06, for a total transaction of $6,361,804.80. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael J. Evanisko sold 1,193 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $144.95, for a total value of $172,925.35. The disclosure for this sale can be found here. Insiders have sold 143,273 shares of company stock worth $20,934,730 over the last 90 days. Corporate insiders own 6.00% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. C J Advisory Inc bought a new position in Iqvia during the first quarter worth $27,000. Baystate Wealth Management LLC purchased a new position in Iqvia in the first quarter valued at about $27,000. Parkside Financial Bank & Trust boosted its stake in Iqvia by 140.2% in the first quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 122 shares during the last quarter. Berman Capital Advisors LLC bought a new stake in Iqvia during the 4th quarter worth approximately $46,000. Finally, ERTS Wealth Advisors LLC bought a new position in shares of Iqvia in the 4th quarter worth $46,000. Institutional investors and hedge funds own 89.69% of the company’s stock.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Article: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.